Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment
Binbin Cheng(Wenzhou Medical University), Xiaoge Niu(Southern Medical University), Shuanghu Wang, Xuchao Yang(Southern Medical University), Jingxuan Chen(Guangdong Pharmaceutical University), Yingfeng Tu(Guangdong Pharmaceutical University), Shuwen Liu(Zhengzhou University), Wei Wang(Capital Medical University), Jianjun Chen(Southern Medical University), Hao Cao, Ting Liu(Qingdao University), Yichang Ren(Southern Medical University), Jingxuan Chen(Southern Medical University)
Cited by 51
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
|Journal for ImmunoTherapy of Cancer|2020|153
Targeting Piezo1 unleashes innate immunity against cancer and infectious disease
|Science Immunology|2020|151